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Abstract
Purpose—The poor prognosis of multiple myeloma with t(4;14) is driven by the fusion of genes 
encoding MMSET and immunoglobulin heavy chain. Specific genes affected by MMSET and 
their clinical implications in Non-MMSET myeloma remain undetermined.
Experimental design—We obtained gene-expression profiles of 1,032 newly diagnosed 
myeloma patients enrolled in Total Therapy 2, Total Therapy 3, Myeloma IX, and HOVON65-
GMMGHD4 trials, and 156 patients from Multiple Myeloma Resource Collection. Probes most 
correlated with MMSET myeloma were selected based on a multivariable linear regression and 
Bonferroni correction, and refined based on the strength of association with survival in Non-
MMSET patients.
Results—Ten MMSET-like probes were associated with poor survival in Non-MMSET 
myeloma. Non-MMSET myeloma patients in the highest quartile of the 10-gene signature 
(MMSET-like myeloma) had 5-year overall survival similar to that of MMSET myeloma (highest 
quartile vs. lowest quartile hazard ratio [HR]=2.0, 95% confidence interval [CI] 1.5-2.8 in 
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MMSET-like myeloma; HR=2.3, 95% CI: 1.6-3.3 in MMSET myeloma). Analyses of MMSET-
like gene signature suggested the involvement of p53 and MYC pathways.
Conclusion—MMSET-like gene signature captures a subset of high-risk myeloma patients 
under-represented by conventional risk stratification platforms, and defines a distinct biological 
subtype.
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Introduction
Multiple myeloma has extremely heterogeneous outcomes. Among many prognostic factors 
utilized in myeloma, translocation t(4;14)(p16.3;q32.3) is an oncogenic event associated 
with poor prognosis. (1) The key molecular target of t(4;14) is multiple myeloma SET 
domain (MMSET) at chromosomal band 4p16.3. (2-5) The detection of MMSET 
overexpression with gene-expression profiling (GEP) consistently identifies a high-risk 
subgroup in multiple myeloma. (6) While the prognostic significance of MMSET is well 
established, the underlying mechanism of its excess risk is poorly understood. Given 
MMSET encodes histone methyltransferase, its overexpression has been attributed to alter 
epigenetic regulation of genes involved in cell cycle progression and DNA damage repair. 
(7) However, downstream gene targets and molecular pathways regulated by MMSET 
remain unclear.
What is also unknown in myeloma is the presence of biological homology shared between 
high-risk and non-high-risk subgroups. This question comes within the context of the recent 
advancement of genetic sequencing, which identified diverse spectrum of disease biology 
that, at times, redefined conventional risk stratification and management. For instance, 
“BRCA-ness” was identified in up to 14% of non-small cell lung cancer and 15% of head 
and neck cancer patients due to epigenetic inactivation of genes responsible for DNA 
damage repair, such as BRCA1 and FNACF. (8) In breast and ovarian cancers, next-
generation sequencing demonstrated the presence of certain genes beyond BRCA1/2, such 
as PALB2, ATM or CHEK2, was strongly associated with an increased risk of cancer 
diagnosis and early death. (9-11) Recent discoveries in solid tumor suggest a substantial 
proportion of cancer patients harbors molecular signatures similar to those of high-risk 
subtypes.
We hypothesize there is an overlap of disease biology between the established high-risk 
myeloma and its non-high-risk counterpart. Specifically, the same genes involved in the 
pathogenesis and adverse outcomes of MMSET myeloma (6) could also be relevant to a 
subset of Non-MMSET patients with poor clinical outcomes (hereby refer to “MMSET-like 
myeloma”). To characterize genes and molecular pathways influencing survival across 
different myeloma subtypes, we assessed expression levels of 54,675 genes in 1,188 newly 
diagnosed multiple myeloma patients. Among 71 genes significantly altered in MMSET 
myeloma, 10 genes most strongly associated with survival were selected and combined into 
a GEP risk score. Patients who did not have detectable MMSET but were at the top quartile 
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of the 10-gene risk score were categorized as MMSET-like myeloma. Five-year survivals 
were similar between patients with MMSET myeloma and MMSET-like myeloma. Pathway 
analysis identified MYC and TP53 transcriptional regulators as lead candidates targeted by 
the observed genes within the risk score. Our findings suggest there is a homology of 
aggressive disease biology and clinical outcomes shared between MMSET myeloma and a 
subset of non-MMSET myeloma.
Methods
Study design
From the NCBI Gene Expression Omnibus (GEO), we downloaded unprocessed CEL files 
from the following datasets: Total Therapy (TT) 2 (N=345, accession number GSE2658, 
NCT00083551); TT 3 (N=214, accession number GSE2658, NCT00081939); HOVON65/
GMMG-HD4, (N=320, accession number GSE19784, ISRCTN64455289); Myeloma IX 
(N=247, accession number GSE15695, ISRCTN68454111); and Multiple Myeloma 
Reference Collection (MMRC) (N=288, accession number GSE26760). The sample size of 
each data set was determined after excluding 8 profiles (accession number GSE19784) that 
were normal plasma cells and 16 patients (accession number GSE26760) who were 
smoldering myeloma (n=11), MGUS (n=2), or plasma cell leukemia (n=3). Anonymized 
patient characteristics of TT trials were obtained from GEO and were identified with the 
same accession numbers. Anonymized patient characteristics of Myeloma IX and 
HOVON65/GMMG-HD4 trials were obtained through personal correspondence with Mark 
van Duin and Ping Wu, respectively. Anonymized patient characteristics of MMRC were 
obtained from Multiple Myeloma Genome Portal. (12) Selected characteristics of patients 
from the five studies are shown in Table 1.
All gene-expression data were derived from CD138+ purified plasma cells of newly 
diagnosed myeloma patients, which were hybridized to Affymetrix Human Genome U133 
Plus 2.0 cDNA microarray (Santa Clara, CA). All raw CEL files were processed using the 
justMAS function in the R statistical programming language, and gene-expression levels 
were log2 transformed. The final dataset included GEPs of 1,188 myeloma patients with 
complete data for age, sex, beta-2 microglobulin, and albumin. For the HOVON65/GMMG-
HD4 trial, FISH data regarding MMSET status was available for 241 patients; MMSET 
status by FISH versus gene expression revealed a correlation of 0.81 (Spearman's rho). For 
the analysis of survival outcomes, we excluded 156 patients from MMRC as it was not a 
clinical trial, and only used the remaining data from 1,032 patients.
Institutional Review Boards of respective institutions approved all studies. All subjects 
provided written informed consents approving the use of their samples for research 
purposes.
Statistical analysis
MMSET myeloma patients, non-MMSET myeloma patients, and genes 
associated with MMSET myeloma—To classify patients into MMSET or Non-MMSET 
myeloma, we used the previously reported microarray model using 700 gene probes to 
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assign subjects into one of seven molecular subtypes. (13) We assessed the association of 
MMSET myeloma with individual expression levels of 54,675 available probes. By using 
linear regression models for each probe and for each study, gene-expression levels were 
dependent variables of MMSET status, age (divided by 50 years or less, 51-60 years, 61-70 
years, 71 years or older), sex, and International Staging System (ISS) stage. (14) For each 
probe, study-specific linear regression coefficients for MMSET myeloma were then 
combined across studies using a random effects meta-analysis. (15) Prior to finalizing the 
probes that were significantly associated with MMSET myeloma, all 700 gene probes used 
in the Arkansas model (13) were removed. We performed a random effects meta-analysis 
after Bonferroni correction for multiple testing (p<0.05/54,675=9.14×10-7). The absolute 
value of the random effects slope parameter for MMSET myeloma was 2 or greater, 
indicating MMSET myeloma had 2-fold or greater changes in log expression of a given 
gene.
Identification of probes associated with survival in Non-MMSET patients—To 
identify probes relevant to survival of non-MMSET patients, results from the 
aforementioned meta-analysis were analyzed by a stepwise variable selection (proc phreg, 
SAS 9.3) in a Cox proportional hazards model. Duration of follow-up was defined by the 
start of treatment until death or censoring. Censoring occurred when a subject reached 5 
years or was lost to follow up. For the initial selection of probes, we included probes that 
passed Bonferroni correction for multiple testing, and those showed log 2 or greater changes 
of expression. For each probe, a minimal p<0.1 in a marginal Cox proportional hazards 
model was set for initial inclusion, and a criteria of p<0.05 was set to retain a probe in the 
model. All models were adjusted for age, sex, ISS stage (14) and treatment. (16-18) The risk 
score was calculated based on the adjusted Cox regression model (Appendix 1).
Validation—To assess the unbiased association of the risk score and survival, we 
conducted a 5-fold cross-validation. (18) Briefly, the original dataset was divided into five 
equal parts, with equal numbers of patients from individual studies in each part. Four of the 
five parts were used to develop a gene signature following the aforementioned procedures 
(training set). The remaining fifth part was used to compute the association of the risk score 
and survival using Cox regression models (test set). Validation was performed five times 
with each part serving as a test set once. Risk scores from five test sets were median-
centered and combined to form an independently scored measure of risk.
Sensitivity analysis—To assess stability of our results, we conducted three separate 
sensitivity analyses (Supplemental Tables 1 and 2). First, we used survival outcomes 
throughout the full follow-up time of up to 98 months instead of censoring at 60 months. 
Second, we excluded patients who were treated with proteasome inhibitor-based regimens, 
such as VTD-PACE and PAD, from the analysis. Third, patients on Myeloma IX trial were 
coded separately if they encountered death or censoring before the second randomization for 
thalidomide maintenance. In all three sensitivity analyses, the main results remained 
unchanged.
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Pathway analysis—To determine biological functions of the identified gene probes, 
pathway analysis was performed using Ingenuity Pathway Analysis software package and 
the molecular signaling database from the Broad Institute (MsigDB). (19) Gene networks 
were constructed using the upstream regulator analysis to identify transcription factors with 
the most interactions with selected genes (Figure 1).
Results
Among 1,032 myeloma patients included in this study, 139 (13.4%) had MMSET myeloma 
defined by GEP (Table 1). (13) In MMSET myeloma, the median age was 59 years (range 
24-89), and 68% were males. Distributions of ISS stage I, II, and III were 48%, 30% and 
22%, respectively. Similar to prior reports (6), MMSET myeloma was associated with a 
higher mortality after adjusting for age, sex, ISS stage and treatment (hazard ratio (HR) 
=1.7, p<0.001).
To determine if the same genes involved in MMSET myeloma were also relevant to survival 
of Non-MMSET myeloma patients, we took the following analytical approach: First, as 
described in the Methods, we obtained GEPs of 1,188 newly diagnosed myeloma patients 
and defined 71 gene probes correlated with MMSET myeloma (Supplemental Table 3). 
From these probes, we further identified those associated with 5-year survival in Non-
MMSET patients and created a 10-gene risk score predictive of survival. Lastly, we 
conducted a functional pathway analysis.
Gene probes correlated with MMSET myeloma
After the random effects meta-analysis, we identified 71 gene probes (0.13%) correlated 
with MMSET myeloma. The selected genes showed 2-fold or greater changes in log-
expressions (range 2.0 to 3.7 or -2.0 to -3.7) in MMSET patients compared to Non-MMSET 
patients, and meta-analytic p-values ranged from 1.9×10-11 to 5.2×10-36 (Supplemental 
Table 3). Genes highly correlated with MMSET myeloma included cyclin D1 (CCND1), 
cyclin D2 (CCND2), a transcription factor Kruppel-like factor 4 (KLF4), ubiquitin carboxyl-
terminal esterase L1 (UCHL1), and alpha-2-glycoprotein (AZGP1) (Supplemental Table 3).
Probes enriched in MMSET myeloma, Non-MMSET myeloma, and survival
From the identified 71 gene probes, 10 genes were strongly associated with 5-year survival 
of Non-MMSET patients (Table 2). AZGP1 and CCND1 were most significantly associated 
with survival (probe-specific HRs: 0.89-0.91 for CCND1 and 1.07-1.14 for AZGP1, 
p<0.001). To define risk scores relevant to survival of non-MMSET myeloma patients, a 
multivariable Cox proportional hazards model was applied to the 10 genes. Risk score 
groups of the first quartile (low-risk) and the fourth quartile (high-risk) were compared 
within Non-MMSET patients in cross-validation. High-risk Non-MMSET patients (here by 
referred as “MMSET-like myeloma”) had a similarly increased risk of mortality (HR=2.0, 
95% confidence interval (CI) 1.5-2.8, p<0.001) comparable to MMSET patients (HR=2.3, 
95% CI 1.6-3.3, p<0.001).
Wu et al. Page 5














To characterize genes and molecular pathways influencing survival across different 
myeloma subtypes, we conducted analysis of the 10 genes associated with 5-year survival in 
MMSET-like myeloma by using IPA (Ingenuity® Systems). Pathway analysis identified 
MYC and TP53 transcriptional regulators as lead candidates for the observed gene 
expression changes within the gene signature risk score (Figure 1). TP53 was identified as a 
transcriptional regulator of four genes (CCND1, PTP4A3, MYBL1, and ROBO1) 
(p=1.9×10-3), and MYC was a transcriptional regulator of five genes (CCND1, AZGP1, 
PTP4A3, MYBL1, and RNF130) (p=3.1×10-4).
Discussion
To characterize genes and molecular pathways influencing survival across myeloma 
subtypes, we assessed expression levels of over 55,000 gene probes from tumor cells 
obtained from 1,188 newly diagnosed myeloma patients. 71 genes were significantly altered 
in patients with the MMSET molecular subtype. Selecting from these genes, 10-gene risk 
score demonstrated similar 5-year survivals between MMSET myeloma and Non-MMSET 
patients categorized as the top quartile risk score (MMSET-like myeloma). A 5-fold cross-
validation was conducted to determine the unbiased association of the risk score and 
survival. Pathway analysis identified MYC and TP53 transcriptional regulators were 
associated with the observed gene-expresssion changes of 10 genes.
Of clinical relevance, our findings suggest an overlap of disease biology between 
conventionally divided groups of high-risk and non-high-risk myelomas. The study findings 
should be interpreted within the context of recent advancement of genetic sequencing, which 
refined tumor subtypes based on recurrent genetic alterations. In ovarian cancer, 
approximately half of the patients were found to have homologous recombination deficiency 
(HRD) mimicking the genetic phenotype of BRCA mutation (i.e. “BRCA-ness”). (20) 
Intriguingly, the presence of HRD in BRCA wild-type patients predicted striking sensitivity 
to PARP inhibition in a prospective trial (overall response rate: 32% with HRD vs. 11% 
without HRD), albeit less than the true BRCA mutated group (66%). Evolving knowledge in 
biological homology across different tumor subtypes proposes a new therapeutic strategy is 
required to improve the outcome of patients with MMSET-like gene signature. As seen in 
differential responsiveness to PARP inhibition in cancers with BRCA-ness, MMSET-like 
subgroup may also benefit from established or investigational regimens developed for high-
risk myeloma, rather than those developed for standard-risk population. Such regimens 
tested in high-risk myeloma include proteasome inhibitors (21-23) and other investigational 
agents aimed at novel targets such as FGFR3, (5) CD38, (24) and MEK pathway. (25) 
Further research needs to validate the role of genomic risk stratification tools to capture 
high-risk population, and to prospectively assess clinical outcome to potential treatment 
options within the identified subgroup.
Another important observation of this study is the demonstration of TP53 and MYC as 
downstream targets of MMSET gene signature. t(4;14) accounts for 15% of myeloma 
population and is linked to universal overexpression of MMSET gene. (3, 4) Histone 
methyltransferase encoded at catalytic SET domain methylates lysine residue of histone, 
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leading to epigenetic regulation of genes involved in cell cycle progression, p53 pathway, 
and integrin signaling. (7) The role of MMSET as a myeloma oncogene is supported by an 
experimental knock-down of MMSET in myeloma cell-lines, which led to decreased 
proliferation and increased apoptosis. (2, 26, 27), Among many targets altered by MMSET 
overexpression, c-myc is an important downstream pathway enhanced by MMSET through 
down-regulation of miR-126. (28, 29) The overlap of p53 and MYC pathways has also been 
described in model systems of other malignancies. In vitro, p53 represses c-myc 
transcription by deacetylation of histone located at c-myc promoter (30) and by miR-145-
mediated gene silencing, (31) and arrests cell cycle. These findings support the primary role 
of MMSET as a regulator of epigenetic machineries, rather than genetic instability, and is 
corroborated by findings from whole exome sequencing which demonstrated only a few 
mutational changes in the t(4;14) subgroup. (32) Taken together, an aggressive clinical 
phenotype of MMSET overexpression is attributable to the fine-tuning of selected genes. 
Functional studies are required to assess direct binding or indirect modulation of 10 genes 
by MSMET and to validate downstream activity of MMSET-like signature converging into 
selected signaling pathways, such as MYC and p53.
Gene-expression profiling is a mature and robust technology with many validated platforms 
in multiple myeloma reported to date. (33) Compared to previously established platforms, 
MMSET-like signature has several unique aspects. First, MMSET-like gene signature was 
developed from a biologically homogeneous population with a single genetically defined 
abnormality, and was applied to the overall population with an aim to select patients 
influenced by similar pathobiology. This sequence of development is reversed from what 
had been done in conventional studies, which performed hierarchical gene clustering among 
biologically heterogeneous population. (34) By using the latter method, a given gene-
expression group can contain several different genetic abnormalities within the subtype, (6) 
which may have led to inconsistent results in predicting therapeutic responses. (35) The 10-
gene signature proposed by the current study was developed from a homogenous subgroup, 
hence may be more representative of a single biological entity and can serve a useful risk 
stratification tool for treatment trials. Second, with the exception of one gene, 10-gene 
signature did not overlap with previously reported platforms such as EMC 92-gene, (34) 
UAMS 70-gene (6) and IFM 15-gene signatures. (36) This finding further supports that 
MMSET-like gene signature represents a distinct biological subtype utilizing a selected set 
of genes. Interestingly, ROBO1 was the only gene within our 10-gene platform that was 
previously reported in another gene expression profile (37) and in a sequencing study as a 
candidate gene in myeloma. (32) Downstream of ROBO1 is associated with E-cadherin 
mediated regulation of WNT signaling in pancreatic cancer, and its functional role in 
myeloma remains to be studied.
We demonstrated 10-gene signature that were significantly altered in MMSET myeloma and 
associated with inferior survival in Non-MMSET myeloma patients. Pathway analysis of the 
MMSET-like gene signature recapitulated clustering of important signaling pathways in 
myeloma, specifically TP53 and MYC pathways. MMSET-like gene expression profile was 
able to capture a distinct biological subtype under-represented by conventional platforms, 
and was strongly linked poor clinical outcome. The proposed gene signature can serve as a 
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reliable screening platform representative of high-risk disease biology, as we move towards 
personalized therapy for myeloma.
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Statement of Translational Relevance
Multiple myeloma is a biologically and clinically heterogeneous disease. The presence of 
biological homology shared between conventional high-risk and non-high-risk myeloma 
subgroups has not been reported to date. We hypothesized that molecular risk 
stratification can capture biological homology between patients with or without MMSET 
overexpression, and be used as a prognostic tool. We identified 10-gene signature 
associated with MMSET myeloma. We obtained gene-expression profiles of 1,032 newly 
diagnosed myeloma patients enrolled in Total Therapy 2, Total Therapy 3, Myeloma IX, 
and HOVON65-GMMGHD4 trials, and 156 patients from Multiple Myeloma Resource 
Collection. Expression of MMSET-like gene signature in Non-MMSET subgroup was 
associated with similarly poor survival. Pathway analysis of MMSET-like gene signature 
revealed the involvement of p53 and MYC signaling pathways. MMSET-like gene 
signature captures a subset of high-risk myeloma patients under-represented by 
conventional risk stratification platforms, and defines a distinct biological subtype.
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Full lines represent direct interactions while dashed lines indicate indirect interactions. An 
arrow pointing from one protein to another indicates that the first protein acts on or activates 
the second protein (at which the arrow is pointing).
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